| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
IT:DIA
DiaSorin S.p.A.
|
Oct 23, 2026 | BUY |
Sell
+37.7% avg upside
10 analysts
|
$95.00
17.97% Upside
|
+4.2% | Β· |
|
FR:BIM
bioMerieux
|
Oct 23, 2026 | HOLD |
Buy
+15.2% avg upside
12 analysts
|
$85.00
6.14% Downside
|
+4.5% | Β· |
|
DE:SHL
Siemens Healthineers AG
|
Oct 16, 2026 | BUY |
Buy
+14.8% avg upside
24 analysts
|
$48.00
11.99% Upside
|
+7.1% | Β· |
|
NL:PHIA
Koninklijke Philips N.V.
|
Oct 12, 2026 | HOLD |
Buy
+24.3% avg upside
21 analysts
|
$25.00
3.05% Upside
|
+23.4% | Β· |
|
GB:SPI
Spire Healthcare
|
Sep 07, 2026 | HOLD |
Strong Buy
+14.9% avg upside
6 analysts
|
$250.00
0.47% Upside
|
+1.0% | Β· |
|
CH:GALD
Galderma Group AG
|
Jul 08, 2026 | HOLD |
Strong Buy
-0.1% avg upside
12 analysts
|
$175.00
9.34% Downside
|
+3.6% | Β· |
|
DE:FYB
Formycon AG
|
May 28, 2026 | BUY |
Strong Buy
+171.2% avg upside
5 analysts
|
$51.00
170.22% Upside
|
-31.8% | Β· |
|
CH:SDZ
Sandoz Group Ltd
|
Mar 23, 2026 | HOLD |
Buy
-14.9% avg upside
12 analysts
|
$65.00
21.06% Downside
|
+15.7% | Β· |
|
GB:DXRX
Diaceutics
|
Jul 10, 2025 | BUY |
Strong Buy
+0.7% avg upside
2 analysts
|
$185.00
9.02% Downside
|
+19.8% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.